羟氯喹临床应用研究进展(5)
[24] Ben-Zvi I， Kivity S， Langevitz P， et al. Hydroxychloroquine： from malaria to autoimmunity[J]. Clin Rev Allergy Immunol， 2012， 42(2)： 145-153.
[25] Huang C， Wang Y， Li X， et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan， China[J]. Lancet， 2020， 395(10223)： 497-506.
[26] Rolain JM， Colson P， Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial， fungal and viral infections in the 21st century[J]. Int J Antimicrob Agents， 2007， 30(4)： 297-308.
[27] Devaux CA， Rolain JM， Colson P， et al. New insights on the antiviral effects of chloroquine against coronavirus： what to expect for COVID-19[J/OL]. Int J Antimicrob Agents， 2020. doi： 10.1016/j.ijantimicag.2020.105938.
[28] Savarino A， Gennero L， Chen HC， et al. Anti-HIV effects of chloroquine： mechanisms of inhibition and spectrum of activity[J]. AIDS， 2001， 15(17)： 2221-2229.
[29] Zou Y， Ling YH， Sironi J， et al. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib[J]. J Thorac Oncol， 2013， 8(6)： 693-702.
[30] Al-Bari MA. Chloroquine analogues in drug discovery： new directions of uses， mechanisms of actions and toxic manifestations from malaria to multifarious diseases[J]. J Antimicrob Chemother， 2015， 70(6)： 1608-1621., http://www.100md.com(张洋)
[25] Huang C， Wang Y， Li X， et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan， China[J]. Lancet， 2020， 395(10223)： 497-506.
[26] Rolain JM， Colson P， Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial， fungal and viral infections in the 21st century[J]. Int J Antimicrob Agents， 2007， 30(4)： 297-308.
[27] Devaux CA， Rolain JM， Colson P， et al. New insights on the antiviral effects of chloroquine against coronavirus： what to expect for COVID-19[J/OL]. Int J Antimicrob Agents， 2020. doi： 10.1016/j.ijantimicag.2020.105938.
[28] Savarino A， Gennero L， Chen HC， et al. Anti-HIV effects of chloroquine： mechanisms of inhibition and spectrum of activity[J]. AIDS， 2001， 15(17)： 2221-2229.
[29] Zou Y， Ling YH， Sironi J， et al. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib[J]. J Thorac Oncol， 2013， 8(6)： 693-702.
[30] Al-Bari MA. Chloroquine analogues in drug discovery： new directions of uses， mechanisms of actions and toxic manifestations from malaria to multifarious diseases[J]. J Antimicrob Chemother， 2015， 70(6)： 1608-1621., http://www.100md.com(张洋)